Junior Research Group Stem Cell Biology, Excellence Cluster REBIRTH, Hannover Medical School, Carl-Neuberg-Str. 1, 30625, Hannover, Germany,
Adv Biochem Eng Biotechnol. 2010;123:107-26. doi: 10.1007/10_2010_74.
The induction of pluripotency in somatic cells is widely considered as a major breakthrough in regenerative medicine, because this approach provides the basis for individualized stem cell-based therapies. Moreover, with respect to cell transplantation and tissue engineering, expertise from bioengineering to transplantation medicine is now meeting basic research of stem cell biology.In this chapter, we discuss techniques, potential and possible risks of induced pluripotent stem (iPS) cells in the light of needs for patient-derived pluripotent stem cells. To this end, we compare these cells with other sources of pluripotent cells and discuss the first encouraging results of iPS cells in pharmacological research, disease modeling and cell transplantation, providing fascinating perspectives for future developments in biotechnology and regenerative medicine.
体细胞多能性的诱导被广泛认为是再生医学的重大突破,因为这种方法为个体化基于干细胞的治疗提供了基础。此外,就细胞移植和组织工程而言,现在从生物工程到移植医学的专业知识正在满足干细胞生物学的基础研究。在这一章中,我们根据患者来源的多能干细胞的需求,讨论诱导多能干细胞(iPS)的技术、潜力和可能风险。为此,我们将这些细胞与其他多能细胞来源进行了比较,并讨论了 iPS 细胞在药理学研究、疾病建模和细胞移植方面的第一个令人鼓舞的结果,为生物技术和再生医学的未来发展提供了引人入胜的前景。